Rallybio Corp has announced a delay in the closing of its merger with Avenzo Therapeutics, originally scheduled for November 6, 2026. This postponement comes as certain conditions related to the listing of the company’s shares have not been satisfied. The delay may impact the company’s planned cash distribution, which was set to occur on November 5, 2026.

The merger is significant for Rallybio, as it seeks to enhance its position in the pharmaceutical preparations industry. The company previously disclosed that the merger agreement was made on May 31, 2026, and aimed to strengthen its operational capabilities and market presence.

Background

Rallybio Corp, incorporated in Delaware, operates within the pharmaceutical preparations sector, classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol RLYB. As an emerging growth company, Rallybio focuses on developing therapies for rare diseases and unmet medical needs. Recent filings include a Form 8-K on the same day as this filing, indicating ongoing activities and developments within the company.

What the Filing Says

The SEC filing states, "Certain conditions related to the listing of the Company’s shares following the closing of the transactions have not been satisfied and, as a result, the parties have determined to postpone the closing to continue seeking the applicable listing approvals." This statement highlights the regulatory hurdles that have led to the merger's delay.

Impact

This delay may affect various stakeholders, including investors, employees, and partners involved with Rallybio and Avenzo Therapeutics. The postponement of the cash distribution could lead to uncertainty among shareholders who were anticipating the distribution based on the original timeline.

What's Next

The filing does not specify what happens next regarding the merger or the cash distribution. However, Rallybio has indicated that it will provide further updates as necessary in compliance with applicable laws and regulations.